Technical Analysis for IPHA - Innate Pharma S.A.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 2.40 | -2.44% | -0.06 |
IPHA closed down 2.44 percent on Thursday, April 25, 2024, on 5 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 14
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Narrow Range Bar | Range Contraction | 0.00% | |
Gapped Down | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
NR7 | Range Contraction | -2.44% | |
Narrow Range Bar | Range Contraction | -2.44% | |
Gapped Up | Strength | -2.44% | |
Oversold Stochastic | Weakness | -2.44% | |
Inside Day | Range Contraction | 1.27% | |
Oversold Stochastic | Weakness | 1.27% | |
Stochastic Buy Signal | Bullish | -1.03% |
Alert | Time |
---|---|
Possible NR7 | about 15 hours ago |
Down 2 % | about 18 hours ago |
Fell Below Previous Day's Low | about 19 hours ago |
Down 1% | about 19 hours ago |
Fell Below 10 DMA | about 19 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/14/2024
Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Immune System Immunotherapy Antibodies Cancer Treatment Monoclonal Antibodies Monoclonal Antibody Antibody Inflammatory Diseases Immunity
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Immune System Immunotherapy Antibodies Cancer Treatment Monoclonal Antibodies Monoclonal Antibody Antibody Inflammatory Diseases Immunity
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.57 |
52 Week Low | 1.81 |
Average Volume | 10,601 |
200-Day Moving Average | 2.65 |
50-Day Moving Average | 2.53 |
20-Day Moving Average | 2.51 |
10-Day Moving Average | 2.43 |
Average True Range | 0.18 |
RSI (14) | 45.95 |
ADX | 20.3 |
+DI | 21.35 |
-DI | 16.38 |
Chandelier Exit (Long, 3 ATRs) | 2.62 |
Chandelier Exit (Short, 3 ATRs) | 2.78 |
Upper Bollinger Bands | 2.75 |
Lower Bollinger Band | 2.27 |
Percent B (%b) | 0.27 |
BandWidth | 19.00 |
MACD Line | -0.04 |
MACD Signal Line | -0.03 |
MACD Histogram | -0.0082 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.45 | ||||
Resistance 3 (R3) | 2.45 | 2.44 | 2.44 | ||
Resistance 2 (R2) | 2.44 | 2.43 | 2.44 | 2.43 | |
Resistance 1 (R1) | 2.42 | 2.42 | 2.42 | 2.42 | 2.43 |
Pivot Point | 2.41 | 2.41 | 2.41 | 2.41 | 2.41 |
Support 1 (S1) | 2.39 | 2.40 | 2.39 | 2.39 | 2.37 |
Support 2 (S2) | 2.38 | 2.39 | 2.38 | 2.37 | |
Support 3 (S3) | 2.36 | 2.38 | 2.36 | ||
Support 4 (S4) | 2.36 |